Amarin, Omthera dip after study knocks fish oil benefit
This article was originally published in Scrip
Executive Summary
A large study showing heart patients failed to benefit from taking fish oil supplements, nicked the shares of two US companies that are focused on prescription-strength medicines.
You may also be interested in...
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Bresch is looking to do a sizable deal
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.